NCT01176513 - GE-148-002: A Phase 2, Open-label, Single-Center Study to Assess GE-148 (18F) Injection PET Imaging to Detect Localized Prostate Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

July 31, 2010

Primary Completion Date

March 31, 2012

Study Completion Date

March 31, 2012

Conditions

Prostate Cancer

Interventions

DRUG

GE-148 (18F)

All subjects will receive an i.v. dose of GE-148 (18F) Injection at 10 mCi (370 MBq) to provide adequate image quality throughout the specified imaging period.

Trial Locations (1)

20892

National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda